Across TCGA pan-cancer cohorts, ANKRD34B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ANKRD34B data layer compared with 21 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ANKRD34B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD34B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, COAD, and ESCA are the cancer types where ANKRD34B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.051	0.684	<.001	24	view →
COAD	OS	Median	II,III,IV	0.168	0.788	.005	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
UCEC	DFS	Median	II,III,IV	0.906	0.441	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ANKRD34B tumor-vs-normal RNA expression · all ANKRD34B data types